Rhizen Pharmaceuticals S.A. Announces Scientific Presentations on the Therapeutic Potential of Their Lead Dual PI3K Delta/Gamma Inhibitor and CRAC Channel Inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013
9/6/2013 9:41:45 AM
La Chaux-de-Fonds, Switzerland, Sept. 6, 2013 (GLOBE NEWSWIRE) -- La Chaux-de-Fonds, Switzerland (6 September 2013): Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the pre-clinical characterization of its lead calcium release activated channel (CRAC) inhibitor, RP3128, for the treatment of respiratory disorders and an oral presentation on the pharmacological profile of its novel, dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, RP6503, in the pulmonary disease systems, at the European Respiratory Society Annual Congress (ERS), to be held from 7-11 September 2013, at Barcelona, Spain.
Help employers find you! Check out all the jobs and post your resume.
comments powered by